RANIBIZUMAB
Information current as at: 1 July 2026
PBAC meeting date: November 2026
Submission Details
- Brand name:
-
- Susvimo®
- Form and strength:
-
- Solution for ocular implant 39.5 mg in 0.395 mL
- Submission sponsor:
- ROCHE PRODUCTS PTY LTD
- Condition/indication:
(therapeutic use) -
- Subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD)
- Listing requested:
- Resubmission to request listing of ranibizumab, for administration via ocular implant, for the treatment of patients with CNV secondary to AMD who have previously demonstrated a response to intravitreal anti‑vascular endothelial growth factor (anti‑VEGF) therapy.
- Funding program:
- PBS General Schedule
- Request authority level:
- Authority Required (Telephone/Online)
- PBAC Submission type:
- New PBS listing (–)
- Comment:
- --
- Other PBAC consideration:
Progress Details
-
Submission received for: - November 2026 PBAC meeting
-
2Opportunity for consumer comment:
- Open 22/07/2026 and close 16/09/2026 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Pending PBAC outcome (see PBAC Outcomes)
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID
a1303
Page last updated
23 July 2026
v.9.19